Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke

Widely prescribed antiplatelets such as aspirin and Plavix have a common problem: By decreasing platelet aggregation, they also increase the risk of uncontrolled bleeding. An experimental drug from Acticor Biotech might be able to cut that bleeding risk, a small first-in-human study has found.